Abstract Background and Objective Standard piperacillin–tazobactam (PT) dosing may be
suboptimal in obesity, but high-dose regimens have not been studied. We prospectively …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …

The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics
of piperacillin and tazobactam administered by prolonged infusion in obese patients …

Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …

Precision dosing of piperacillin/tazobactam in obese patients is compromised by sparse
information on target-site exposure. We aimed to evaluate the appropriateness of current …

Study Objective To evaluate the steady‐state pharmacokinetic and pharmacodynamic
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …

The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Objectives: To evaluate the pharmacodynamic exposure of piperacillin/tazobactam across
the renal function range using 4.5 or 3.375 g dosing regimens. Methods: A 5000-patient …

Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

Sir, The combination of piperacillin and tazobactam has been shown to be efficacious for the
treatment of intra-abdominal infections, skin and soft tissue infections, bacteraemia and …